Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized crossover study of abiraterone versus cabazitaxel in second-line metastatic castration-resistant prostate cancer
2015-000270-36Phase 2Terminated
- Sponsor
- Umeå University Hospital
- Start
- Mar 2015
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Umeå University Hospital. Primary endpoint: PSA response by AKR1C3 status during first treatment period. Started Mar 2015; status: terminated.
02
Drugs
abirateronecabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2015-000270-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000270-36.